Abstract:Background Neuroblastoma (NB) is one of the deadliest paediatric solid tumours due to its rapid proliferative characteristics. Amplified copies of MYCN are considered the most important marker for the prediction of tumour relapse and progression in NB, but they were only detected in 20–30% of NB patients, indicating there might be other oncogenes in the development of NB. The far upstream element binding protein 1 (FUBP1) was first identified as a transcriptional regulator of the proto-oncogene MYC. However, the expression and role of FUBP1 in NB have not been documented. Methods FUBP1 expression was analysed from GEO database and verified by immunohistochemistry (IHC) and western blotting (WB) in NB tissues and cell lines. Cell proliferation and apoptosis were detected by Cell Counting Kit-8, Colony formation assay, EDU, TUNEL staining and flow cytometric analysis. Several glycolytic metabolites production was confirmed by ELISA and oxygen consuming rate (OCR). Luciferase assay, WB, chromatin immunoprecipitation (CHIP) were used to explore the mechanisms of the effect of FUBP1 on NB. Results FUBP1 mRNA levels were increased along with the increase in International Neuroblastoma Staging System (INSS) stages. High expression of FUBP1 with low N-Myc expression accounted for 44.6% of NB patient samples ( n = 65). In addition, FUBP1 protein levels were remarkably increased with NB malignancy in the NB tissue microarray (NB: n = 65; ganglioneuroblastoma: n = 31; ganglioneuroma: n = 27). Furthermore, FUBP1 expression was negatively correlated with patient survival rate but positively correlated with ki67 content. In vitro experiments showed that FUBP1 promotes NB cell proliferation and inhibits cell apoptosis via enhancing glycolysis and ATP production. Mechanistically, FUBP1 inhibited the degradation of HIF1α via downregulation of Von Hippel-Lindau (VHL), the E3 ligase for HIF1α, resulting in upregulation of lactate dehydrogenase isoform B (LDHB) expression to enhance glycolysis. Overexpressed or silenced N-Myc could not regulate FUBP1 or LDHB levels. Conclusions Taken together, our findings demonstrate for the first time that elevated FUBP1 promotes NB glycolysis and growth by targeting HIF1α rather than N-Myc, suggesting that FUBP1 is a novel and powerful oncogene in the development of NB independent of N-Myc and may have potential in the diagnosis and treatment of NB.

PHF20 Collaborates with PARP1 to Promote Stemness and Aggressiveness of Neuroblastoma Cells Through Activation of SOX2 and OCT4

Mutations That Disrupt PHOXB Interaction with the Neuronal Calcium Sensor HPCAL1 Impede Cellular Differentiation in Neuroblastoma

PHF20 Promotes Glioblastoma Cell Malignancies Through a WISP1/BGN-Dependent Pathway

Smoothened-Independent Activation of Hedgehog Signaling by Rearranged During Transfection Promotes Neuroblastoma Cell Proliferation and Tumor Growth

Therapeutic Targeting of MZF1-AS1/PARP1/E2F1 Axis Inhibits Proline Synthesis and Neuroblastoma Progression.

HNF4A-AS1-encoded small peptide promotes self-renewal and aggressiveness of neuroblastoma stem cells via eEF1A1-repressed SMAD4 transactivation

Retraction Note: HNF4A-AS1/hnRNPU/CTCF Axis As a Therapeutic Target for Aerobic Glycolysis and Neuroblastoma Progression.

Endogenous Authentic OCT4A Proteins Directly Regulate FOS/AP-1 Transcription in Somatic Cancer Cells.

Risk-Associated Long Noncoding RNA FOXD3-AS1 Inhibits Neuroblastoma Progression by Repressing PARP1-Mediated Activation of CTCF

PHF20L1 antagonizes SOX2 proteolysis triggered by the MLL1/WDR5 complexes

Krüppel‐like Factor 9 Promotes Neuroblastoma Differentiation Via Targeting the Sonic Hedgehog Signaling Pathway

PHF20L1 as a H3K27me2 reader coordinates with transcriptional repressors to promote breast tumorigenesis

METTL3-induced lncARSR aggravates neuroblastoma tumorigenic properties through stabilizing PHOX2B

PP4R1 Induced Cancer Stemness by Upregulating the Expression of OCT4 Via the MAPK/ERK Pathway in NSCLC

FUBP1 Promotes Neuroblastoma Proliferation Via Enhancing Glycolysis-a New Possible Marker of Malignancy for Neuroblastoma

HN1L promotes stem cell-like properties by regulating TGF-β signaling pathway through targeting FOXP2 in prostate cancer

Silencing of the PHLDA1 leads to global proteome changes and differentiation pathways of human neuroblastoma cells

EZH2 regulates neuroblastoma cell differentiation via NTRK1 promoter epigenetic modifications

NARF is a Hypoxia-Induced Coactivator for OCT4-mediated Breast Cancer Stem Cell Specification

ALKB homolog 5 (ALKBH5)-induced circPUM1 upregulation facilitated the progression of neuroblastoma via miR-423-5p/PA2G4 axis

Regulation of Neuroblastoma Differentiation by Forkhead Transcription Factors FOXO1/3/4 Through the Receptor Tyrosine Kinase PDGFRA